-

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2022

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2022 of $1.13 per share on the company’s common stock. The dividend is payable on December 6, 2022 to shareholders of record at the close of business on November 22, 2022. The ex-dividend date is November 21, 2022.

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Contacts

Press:
Jake Sargent
jsargen3@ITS.JNJ.com

Investors:
Jessica Moore
jmoore29@its.jnj.com

Sarah Wood
swood15@its.jnj.com

Johnson & Johnson


Release Versions

Contacts

Press:
Jake Sargent
jsargen3@ITS.JNJ.com

Investors:
Jessica Moore
jmoore29@its.jnj.com

Sarah Wood
swood15@its.jnj.com

More News From Johnson & Johnson

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, 2026. Management will participate in a Fireside Chat at 11:10 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available app...

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the specialized care they need to live, see and smile. The Company has also planned to contribute an additional $20 million toward programs and impact investments that empower health workers to deliver cardiac, vision and surgical care in their communiti...

Johnson & Johnson reports Q4 and Full-Year 2025 results

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuros...
Back to Newsroom